advertisement
Abstract #107976 Published in IGR 23-4
Long-Term Visual Field Outcomes After Ahmed Glaucoma Valve Implantation
Khaliliyeh D; de Gainza A; Morales E; Caprioli JAmerican Journal of Ophthalmology 2023; 251: 173-188
PURPOSE: To measure visual field (VF) rates of change after Ahmed Glaucoma Valve (AGV) implantation and to investigate risk factors for progression. DESIGN: Retrospective, clinical cohort study. METHODS: Patients who underwent AGV implantation with at least 4 eligible postoperative VFs and 2 years of follow-up were included. Baseline, intraoperative, and postoperative data were collected. VF progression was explored with 3 methods: mean deviation (MD) rate; glaucoma rate index (GRI); and pointwise linear regression (PLR). For a subset of eyes with sufficient preoperative and postoperative VFs, rates were compared between the 2 periods. RESULTS: A total of 173 eyes were included. The intraocular pressure (IOP) and number of glaucoma medications were significantly reduced from a median (interquartile range [IQR]) of 23.5 (12.1) mm Hg at baseline to 12.8 (4.0) mm Hg at final follow-up, and from (mean ± SD) 3.3 ± 1.2 to 2.2 ± 1.4, respectively. A total of 38 eyes (22%) showed VF progression, and 101 eyes (58%) were stable as assessed by all 3 methods, which accounted for 80% of all eyes. The rate of VF decline by MD and GRI was a median (IQR) of -0.30 (0.8) dB/y and -2.30 (10.6) (of -100), respectively. When comparing progression before and after surgery, the reduction was not statistically significant with any of the methods. The peak IOP (after 3 postoperative months) was associated with VF deterioration, with a 7% increase in risk per each additional millimeter of mercury (mm Hg). CONCLUSIONS: To our knowledge, this is the largest published series reporting long-term VF outcomes after glaucoma drainage device implantation. There is a continued, significant rate of VF decline after AGV surgery.
From the Glaucoma Division (D.K., E.M., J.C.).
Full article